Interpreting the results of the VERTIS‐CV trial: Is this the end of the “class effect” perspective?
Explore this paper's citation graph
Summary
This paper presents a systematic literature review of insulin replacement therapy and its applications in clinical practice and in patients with type 2 diabetes.
- Type
- article
- Published
- 2020-09-04
- Cited by
- 12
- References
- 21
- OpenAlex
- https://openalex.org/W32886864
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:221503067
Keywords
Computer science
References
- Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
- Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors.
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
- [A randomized trial of intensive versus standard blood pressure control].
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- Comparison of MDRD, CKD-EPI, and Cockcroft-Gault equation in relation to measured glomerular filtration rate among a large cohort with diabetes.
- SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review
- Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS‐CV)
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- Ertugliflozin for the treatment of type 2 diabetes.
- Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence.
- Class effects of SGLT2 inhibitors on cardiorenal outcomes
- Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
- Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis
- Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?
- A Randomized Trial of Intensive versus Standard Blood-Pressure Control.
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
Cited by
- Sodium–glucose co‐transporter‐2 inhibitors and arterial stiffness: Class effect or drug effect?
- Management of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics
- Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials
- Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
- Sodium-Glucose Co-transporter 2 Inhibitors Versus Metformin as the First-Line Treatment for Type 2 Diabetes: Is It Time for a Revolution?
- The effect of dapagliflozin on ventricular arrhythmias, cardiac arrest, or sudden death in people with heart failure: a tick in another box for sodium-glucose cotransporter 2 inhibitors
- Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.
- A Horse, a Jockey, and a Therapeutic Dilemma: Choosing the Best Option for a Patient with Diabetes and Coronary Artery Disease
- Dual sodium-glucose cotransporter (SGLT) 1/2 versus pure SGLT2 inhibitors: two distinct drug categories or one class with multiple faces?
- Progenitor Cell Function and Cardiovascular Remodelling Induced by SGLT2 Inhibitors.
- Study on Differences of Metabolites among Different Ganoderma Species with Comprehensive Metabolomics
- Treatment options following metformin in primary prevention populations with type 2 diabetes: which is the right road to take?
Related papers
No related papers recorded.